Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Samuel A Funt

Showing results (71-80 of 78) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 78 results.
Nature|May 31, 2022
Author Correction: Fundamental immune-oncogenicity trade-offs define driver mutation fitnessDavid Hoyos, Roberta Zappasodi, Isabell Schulze, et al.
Nature|May 11, 2022
Fundamental immune-oncogenicity trade-offs define driver mutation fitnessDavid Hoyos, Roberta Zappasodi, Isabell Schulze, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2022
Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II TrialSamuel A Funt, Michael Lattanzi, Karissa Whiting, et al.
Genome Medicine|June 1, 2021
Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patientsDana W Y Tsui, Michael L Cheng, Maha Shady, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2019
Cancer Susceptibility Mutations in Patients With Urothelial MalignanciesMaria I Carlo, Vignesh Ravichandran, Preethi Srinavasan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 2, 2023
Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient OutreachSeyram A Doe-Tetteh, Sabrina Y Camp, Dalicia Reales, et al.
Nature Communications|December 23, 2022
Author Correction: FOXA1 repression drives lineage plasticity and immune heterogeneity in bladder cancers with squamous differentiationJoshua I Warrick, Wenhuo Hu, Hironobu Yamashita, et al.
Nature Communications|November 3, 2022
FOXA1 repression drives lineage plasticity and immune heterogeneity in bladder cancers with squamous differentiationJoshua I Warrick, Wenhuo Hu, Hironobu Yamashita, et al.
Pageof 8

Showing results (71-80 of 78) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 78 results.
Nature|May 31, 2022
Author Correction: Fundamental immune-oncogenicity trade-offs define driver mutation fitnessDavid Hoyos, Roberta Zappasodi, Isabell Schulze, et al.
Nature|May 11, 2022
Fundamental immune-oncogenicity trade-offs define driver mutation fitnessDavid Hoyos, Roberta Zappasodi, Isabell Schulze, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2022
Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II TrialSamuel A Funt, Michael Lattanzi, Karissa Whiting, et al.
Genome Medicine|June 1, 2021
Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patientsDana W Y Tsui, Michael L Cheng, Maha Shady, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2019
Cancer Susceptibility Mutations in Patients With Urothelial MalignanciesMaria I Carlo, Vignesh Ravichandran, Preethi Srinavasan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 2, 2023
Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient OutreachSeyram A Doe-Tetteh, Sabrina Y Camp, Dalicia Reales, et al.
Nature Communications|December 23, 2022
Author Correction: FOXA1 repression drives lineage plasticity and immune heterogeneity in bladder cancers with squamous differentiationJoshua I Warrick, Wenhuo Hu, Hironobu Yamashita, et al.
Nature Communications|November 3, 2022
FOXA1 repression drives lineage plasticity and immune heterogeneity in bladder cancers with squamous differentiationJoshua I Warrick, Wenhuo Hu, Hironobu Yamashita, et al.
Pageof 8